Amrutha Menon
Research Subjects
Research Interests
Amrutha Menon has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ajeet Kaushik
Florida Polytechnic University
1 shared publication - Arshid Numan
Sunway Centre for Electrochemical Energy and Sustainable Technology (SCEEST), Faculty of Engineering and Technology, Sunway University, Bandar Sunway, Malaysia
1 shared publication - Chit Laa Poh
ALPS Global Holding Berhad, The ICON, East Wing Tower, No. 1, Jalan 1/68F, Off Jalan Tun Razak, Kuala Lumpur 50400, Malaysia
1 shared publication - Claire Mary Savio
Department of Engineering, Amity University Dubai, Dubai International Academic City P.O. Box 345019, United Arab Emirates
1 shared publication - Jayesh Cherusseri
Department of Chemistry (BK21 FOUR) Research Institute of Advanced Chemistry Gyeongsang National University Jinju Republic of Korea
1 shared publication - Kanwal Khalid
Centre for Virus and Vaccine Research, School of Medical and Life Sciences, Sunway University, Bandar Sunway, Petaling Jaya 47500, Selangor, Malaysia
1 shared publication
Latest Publications
- Open Access
- 18 October 2022
- Published by MDPI AG in Biosensors
- Vol. 12 (10) , 890
SARS-CoV-2-on-Chip for Long COVID Management
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a “wicked evil” in this century due to its extended progression and huge human mortalities. Although the diagnosis of SARS-CoV-2 viral infection is made simple and practical by employing reverse transcription polymerase chain reaction (RT-PCR) investigation, the process is costly, complex, time-consuming, and requires experts for testing and the constraints of a laboratory. Therefore, these challenges have raised the paradigm of on-site portable biosensors on a single chip, which reduces human resources and enables remote access to minimize the overwhelming burden on the existing global healthcare sector. This article reviews the recent advancements in biosensors for long coronavirus disease (COVID) management using a multitude of devices, such as point-of-care biosensors and lab-on-chip biosensors. Furthermore, it details the shift in the paradigm of SARS-CoV-2-on-chip biosensors from the laboratory to on-site detection with intelligent and economical operation, representing near-future diagnostic technologies for public health emergency management.
- 18 October 2022
- Published by MDPI AG in Biosensors
- Vol. 12 (10) , 890
Open AccessSARS-CoV-2-on-Chip for Long COVID Management
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a “wicked evil” in this century due to its extended progression and huge human mortalities. Although the diagnosis of SARS-CoV-2 viral infection is made simple and practical by employing reverse transcription polymerase chain reaction (RT-PCR) investigation, the process is costly, complex, time-consuming, and requires experts for testing and the constraints of a laboratory. Therefore, these challenges have raised the paradigm of on-site portable biosensors on a single chip, which reduces human resources and enables remote access to minimize the overwhelming burden on the existing global healthcare sector. This article reviews the recent advancements in biosensors for long coronavirus disease (COVID) management using a multitude of devices, such as point-of-care biosensors and lab-on-chip biosensors. Furthermore, it details the shift in the paradigm of SARS-CoV-2-on-chip biosensors from the laboratory to on-site detection with intelligent and economical operation, representing near-future diagnostic technologies for public health emergency management.
- Top Cited PapersOpen Access
- 29 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11502
miRNA: A Promising Therapeutic Target in Cancer
MicroRNAs are small non-coding RNAs that regulate several genes post-transcriptionally by complementarity pairing. Since discovery, they have been reported to be involved in a variety of biological functions and pathologies including cancer. In cancer, they can act as a tumor suppressor or oncomiR depending on the cell type. Studies have shown that miRNA-based therapy, either by inhibiting an oncomiR or by inducing a tumor suppressor, is effective in cancer treatment. This review focusses on the role of miRNA in cancer, therapeutic approaches with miRNAs and how they can be effectively delivered into a system. We have also summarized the patents and clinical trials in progress for miRNA therapy.
- 29 September 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11502
Top Cited PapersOpen AccessmiRNA: A Promising Therapeutic Target in Cancer
MicroRNAs are small non-coding RNAs that regulate several genes post-transcriptionally by complementarity pairing. Since discovery, they have been reported to be involved in a variety of biological functions and pathologies including cancer. In cancer, they can act as a tumor suppressor or oncomiR depending on the cell type. Studies have shown that miRNA-based therapy, either by inhibiting an oncomiR or by inducing a tumor suppressor, is effective in cancer treatment. This review focusses on the role of miRNA in cancer, therapeutic approaches with miRNAs and how they can be effectively delivered into a system. We have also summarized the patents and clinical trials in progress for miRNA therapy.